In the delCDC42 group of patients, the frequency of tumours with 2 or more amplifications of the stemness gene (a very poor prognostic factor) was 78% (28/36), versus 58% (63/108) in the normal or amplified CDC42 group (p = 0.045). Here, CDC42 is linked to neoplasm.